Optimer announces postive Phase II data

Optimer Pharmaceuticals has announced positive Phase III data from a trial of Prulifloxacin for infectious diarrhea. The drug, which is given in a once-daily dose, met the primary endpoint, and had a safety profile similar to that of a placebo. The study was conducted in Mexico and Peru, in patients who had traveler's diarrhea.

"We are encouraged by the positive data, which shows superiority of Prulifloxacin over placebo," said Michael Chang, President and CEO of Optimer Pharmaceuticals. "We believe these results provide a solid foundation for pursuing a New Drug Application with the FDA, assuming similar data from a second Phase 3 trial."

- here's Optimer's release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.